The European Medicines Agency (EMA) says that the report from the research group at Oslo Rikshospitalet on the connection between AstraZeneca vaccine and blood clots has not been assessed by them.
On Thursday, the EMA gave the vaccine the green light after it has been investigated for possible connections with blood clots. Norwegian researchers, led by Pål André Holme at Rikshospitalet, concluded on Thursday with such a connection.
– We have considered everything that was available to us until yesterday, so if something more has come today, it is not in our basis. But we have assessed the Norwegian conditions before. If there is a study that has come out today, we have not evaluated it yet. But it will be part of our monitoring of the situation. This is a temporary conclusion, says Sabine Strauss, chair of the audit’s safety committee.
The experts have worked on the basis of a hypothesis that the AstraZeneca vaccines triggered an unexpected immune reaction in the sick health workers, who have triggered the system so that a combination of blood clots and low platelets has been obtained.
Chief physician and professor Pål Andre Holme “Our theory that this is a strong immune response that most likely comes after the vaccine, has been found. In collaboration with the section for advanced platelet immunology at UNN, we have now detected specific antibodies against platelets that can give such an image, which we know from other parts of the medicine, but then with drugs as the triggering cause“, the superior explains.
– You say most likely?
“We have the reason. And there is no other thing than the vaccine that can explain that we have received that immune response”, says Holme.
– Why is it nothing more than the vaccine?
– Because we have no other history in these patients that can give such a strong immune response. I’m pretty sure it’s these antibodies that’s the cause, and I see no other reason than that it’s the vaccine that triggers it.
A British man has died and four others have suffered a dangerous blood clotting condition after being given the AstraZeneca vaccine, the UK Medicines and Healthcare products Regulatory Agency (MHRA) confirmed on Thursday.
The five men, aged between 19 and 59, suffered from Cerebral Venous Sinus Thrombosis (CVST), although the MHRA said it did not know whether it had been directly caused by the vaccine.
Lithuania is the latest to suspend use of AstraZeneca’s Covid vaccine as “a precaution” until the European Medicines Agency gives a final evaluation of its safety, the country’s health minister Arturas Dulkys has said.
“We are taking the decision now, because over the previous few hours we have received three reports about serious, unexpected, unwanted thromboembolic cases in patients who were given the AstraZeneca vaccine in Lithuania”, the head of the country’s medicine authority Gytis Andrulionis said. “We do not have proof whether this is a coincidence or due to the vaccine.”
Dutch side effects laboratory Lareb received ten reports “in which thrombosis or embolism may have played a role” after an AstraZeneca vaccine was administered, the lab said on Monday.
Lareb stressed that none of these reports involved serious, rare signs of clot formation in combination with a decreased number of blood platelets in adults under 50 years of age, as Denmark and Norway reported they received. “Lareb has not seen any reports with this specific image so far,” the organization said.
The nurse from the state hospital in Zwettl was admitted to the intensive care unit of the Vienna General Hospital last weekend. The 49-year-old then died as a result of severe coagulation disorders. In order to clarify the cause of death of the nurse, an autopsy will be carried out at the Vienna General Hospital. The deceased had received the first dose of the Covid-19 vaccine from AstraZeneca in Lower Austria ten days before admission to the intensive care unit.
A 35-year-old colleague of the deceased was also in inpatient treatment in the internal department at the Zwettl State Hospital after her vaccination.